Axl/Gas6/NFB signalling in schwannoma pathological proliferation, adhesion and survival

TAM family receptor tyrosine kinases comprising Tyro3 (Sky), Axl, and Mer are overexpressed in some cancers, correlate with multidrug resistance and contribute to tumourigenesis by regulating invasion, angiogenesis, cell survival and tumour growth. Mutations in the gene coding for a tumour suppressor merlin cause development of multiple tumours of the nervous system such as schwannomas, meningiomas and ependymomas occurring spontaneously or as part of a hereditary disease neurofibromatosis type 2. The benign character of merlin-deficient tumours makes them less responsive to chemotherapy. We previously showed that, amongst other growth factor receptors, TAM family receptors (Tyro3, Axl and Mer) are significantly overexpressed in schwannoma tissues. As Axl is negatively regulated by merlin and positively regulated by E3 ubiquitin ligase CRL4DCAF1, previously shown to be a key regulator in schwannoma growth we hypothesized that Axl is a good target to study in merlin-deficient tumours. Moreover, Axl positively regulates the oncogene Yes-associated protein, which is known to be under merlin regulation in schwannoma and is involved in increased proliferation of merlin-deficient meningioma and mesothelioma. Here, we demonstrated strong overexpression and activation of Axl receptor as well as its ligand Gas6 in human schwannoma primary cells compared to normal Schwann cells. We show that Gas6 is mitogenic and increases schwannoma cell-matrix adhesion and survival acting via Axl in schwannoma cells. Stimulation of the Gas6/Axl signalling pathway recruits Src, focal adhesion kinase (FAK) and NF k B. We showed that NF k B mediates Gas6/Axl-mediated overexpression of survivin, cyclin D1 and FAK, leading to enhanced survival, cell-matrix adhesion and proliferation of schwannoma. We conclude that Axl/FAK/Src/NF k B pathway is relevant in merlin-deficient tumours and is a potential therapeutic target for schwannoma and other merlin-deficient tumours.

[1]  Xiance Sun,et al.  Differential Expression of Axl and Correlation with Invasion and Multidrug Resistance in Cancer Cells , 2012, Cancer investigation.

[2]  C. Hanemann,et al.  Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival , 2012, Oncogene.

[3]  A. Dhillon,et al.  Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL , 2012, Oncogene.

[4]  M. Giovannini,et al.  Merlin/NF2 Functions Upstream of the Nuclear E3 Ubiquitin Ligase CRL4DCAF1 to Suppress Oncogenic Gene Expression , 2011, Science Signaling.

[5]  P. Manley,et al.  Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. , 2011, Neuro-oncology.

[6]  J. Fletcher,et al.  AXL regulates mesothelioma proliferation and invasiveness , 2011, Oncogene.

[7]  Jun Du,et al.  Lysophosphatidic Acid Induces MDA-MB-231 Breast Cancer Cells Migration through Activation of PI3K/PAK1/ERK Signaling , 2010, PloS one.

[8]  Y. Nishizawa,et al.  Involvement of Src family kinase activation in angiotensin II-induced hyperresponsiveness of rat bronchial smooth muscle , 2010, Peptides.

[9]  J. Kissil,et al.  Merlin in organ size control and tumorigenesis: Hippo versus EGFR? , 2010, Genes & development.

[10]  L. Chiriboga,et al.  ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. , 2010, Neuro-oncology.

[11]  Jonathan A. Cooper,et al.  Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus , 2010, Cell.

[12]  K. Pienta,et al.  GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. , 2010, Neoplasia.

[13]  C. Matthies,et al.  Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244 , 2010, Neurobiology of Disease.

[14]  L. Wakefield,et al.  Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer. , 2010, Cancer letters.

[15]  C. Hanemann,et al.  Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ , 2009, Histopathology.

[16]  J. R. Peterson,et al.  PAK kinase regulates Rac GTPase and is a potential target in human schwannomas , 2009, Experimental Neurology.

[17]  Sylwia Ammoun,et al.  Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. , 2008, Cancer research.

[18]  V. Golubovskaya,et al.  FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. , 2008, Carcinogenesis.

[19]  A. Kaye,et al.  Expression of ErbB-1 and 2 in vestibular schwannomas , 2007, Journal of Clinical Neuroscience.

[20]  H. Garewal,et al.  A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors , 2007, Oncogene.

[21]  C. Hanemann,et al.  Differential gene expression between human schwannoma and control Schwann cells , 2006, Neuropathology and applied neurobiology.

[22]  L. Medeiros,et al.  The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. , 2006, Experimental hematology.

[23]  B. Dahlbäck,et al.  Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. , 2006, Cytokine & growth factor reviews.

[24]  F. Lang,et al.  PI3 Kinase and PDK1 in the Regulation of the Electrogenic Intestinal Dipeptide Transport , 2006, Cellular Physiology and Biochemistry.

[25]  Paloma Valverde,et al.  Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation. , 2005, Biochemical and biophysical research communications.

[26]  S. Jhanwar,et al.  The NF2 Tumor Suppressor Gene Product, Merlin, Inhibits Cell Proliferation and Cell Cycle Progression by Repressing Cyclin D1 Expression , 2005, Molecular and Cellular Biology.

[27]  C. Hanemann,et al.  Reduced Apoptosis Rates in Human Schwannomas , 2005, Brain pathology.

[28]  C. Hanemann,et al.  Pathological Adhesion of Primary Human Schwannoma Cells is Dependent on Altered Expression of Integrins , 2003, Brain pathology.

[29]  K. Mielke,et al.  Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. , 2003, Human molecular genetics.

[30]  Hongtae Kim,et al.  Inhibition of ras-mediated activator protein 1 activity and cell growth by merlin. , 2002, Molecules and cells.

[31]  C. Chi,et al.  Clinical significance of AXL kinase family in gastric cancer. , 2002, Anticancer research.

[32]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Grafe,et al.  Enhanced Proliferation and Potassium Conductance of Schwann Cells Isolated from NF2 Schwannomas Can Be Reduced by Quinidine , 2000, Neurobiology of Disease.

[34]  K. Kosik,et al.  δ-catenin, an Adhesive Junction–associated Protein Which Promotes Cell Scattering , 1999, The Journal of cell biology.

[35]  E. Liu,et al.  Determinants for transformation induced by the Axl receptor tyrosine kinase , 1998, Oncogene.

[36]  G. Sledge,et al.  Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth , 1997, Molecular and cellular biology.

[37]  G. Stoll,et al.  Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs , 1997, Acta Neuropathologica.

[38]  C. Basilico,et al.  Cleavage and release of a soluble form of the receptor tyrosine kinase ARK in vitro and in vivo , 1996, Journal of cellular physiology.

[39]  M. Sliwkowski,et al.  Identification of Gas6 as a growth factor for human Schwann cells , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  H. Varmus,et al.  Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation. , 1995, Oncogene.

[41]  C. Der,et al.  Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*) , 1995, The Journal of Biological Chemistry.

[42]  H. Coste,et al.  The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. , 1991, The Journal of biological chemistry.

[43]  H. Earp,et al.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.

[44]  M. Kazanietz,et al.  NFkappaB-independent signaling to the cyclin D1 gene by Rac. , 2007, Cell cycle.

[45]  M. Azari,et al.  TNFalpha mediates Schwann cell death by upregulating p75NTR expression without sustained activation of NFkappaB. , 2005, Neurobiology of disease.

[46]  Hongtae Kim,et al.  Inhibition of NF-kappaB activation by merlin. , 2002, Biochemical and biophysical research communications.

[47]  R. Verardo,et al.  Gas6 anti-apoptotic signaling requires NF-kappa B activation. , 2001, The Journal of biological chemistry.